ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor
Singer DE, Atlas SJ, Go AS, Lopes RD, Lubitz SA, McManus DD, Revkin JH, Mills D, Crosson LA, Lenane JC, Aronson RS. ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor. American Heart Journal 2022, 249: 76-85. PMID: 35472303, DOI: 10.1016/j.ahj.2022.04.005.Peer-Reviewed Original ResearchConceptsOral anticoagulant therapyEfficacy end pointSafety end pointUndiagnosed atrial fibrillationAtrial fibrillationEnd pointAF screeningLong-term oral anticoagulant therapyIndividuals age 70 yearsRate of strokeProportion of patientsScreen-detected casesNovel coronavirus disease 2019 (COVID-19) pandemicAge 70 yearsParoxysmal atrial fibrillationCoronavirus disease 2019 (COVID-19) pandemicPrimary care practicesTarget sample sizeDisease 2019 pandemicLong-term screeningElectronic health recordsBleeding outcomesScreening armAF burdenUsual care